ALK and non-small cell lung carcinoma: A growing body of evidence demonstrate that application of surgery and radiotherapy to treat these areas, in combination with the systemic targeted therapy, lead to significant improvement of overall survival and disease control in patients with stage IV ALK‐positive NSCLC [55, 79].